In multiple ER+ breast cancer cell lines, the WEE1 inhibitor AZD1775 (MK1775), which works to decrease WEE1 activity at the G2/M checkpoint, has been shown to increase sensitivity in cells resistant to CDK4/6 inhibitors and cause cell death [72]. This evidence concerns the gene ESR1 and breast cancer.